Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
68Ga-NYM096 in Indeterminate Renal Masses
NCT07768306Phase 1Not yet recruiting
- Sponsor
- Norroy Bioscience
- Start
- Sep 2026
- Primary completion
- Mar 2027
01
Overview
Phase 1, open-label, single-arm trial of 68Ga-NYM096 in clear cell renal cell carcinoma (ccRCC), sponsored by Norroy Bioscience. Primary endpoint: Incidence of Treatment-Emergent Adverse events at 4 days. Planned start Sep 2026; status: not yet recruiting.
02
Drugs
68Ga-NYM096
03
Conditions
clear cell renal cell carcinoma (ccRCC)
Beyond the preview
Go deeper on NCT07768306.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07768306.